Roche and Immunomedics have expanded their checkpoint inhibitor-ADC partnership from TNBC to include other solid tumours: UC and NSCLC. What promise does combining ADC Trodelvy and checkpoint inhibitor Tecentriq have in overcoming unmet needs in these cancer types?